
WHAT IS CLAIMED IS:

1. A long-acting injectable composition comprising:

a) an effective amount of at least one parasiticidal isoxazoline active agent, which is a compound of formula (Ic):



(Ic)

or a pharmaceutically acceptable salt therof;

wherein

X^1, X^2 and X^3 are each independently halogen, C_1-C_3alkyl or C_1-C_3 haloalkyl;

b) at least one pharmaceutically acceptable polymer which is a liquid PEG;

c) optionally, at least one co-solvent wherein said co-solvent is a polar solvent miscible in water;

d) optionally, an antioxidant; and

e) optionally at least one pharmaceutically acceptable additive, excipient or mixtures thereof


wherein no other pharmaceutically acceptable polymers are present.

2. The long-acting injectable composition according to claim 1, wherein X^1 is Cl; X^2 is F; and X^3 is $–CF_3$.

3. The long-acting injectable composition according to claim 1, wherein the isoxazoline active agent is enriched in an enantiomer.

4. The long-acting injectable composition according to claim 1, wherein the isoxazoline active agent is a compound of formula (*S*)-Ic:

,



(*S*)-Ic


wherein X^1, X^2 and X^3 are independently chloro, fluoro or CF_3;
or a pharmaceutically acceptable salt thereof.

5. The long-acting injectable composition according to any one of claims 1 to 4, wherein the liquid PEG is PEG 200, PEG 300 or PEG 400, or a mixture thereof.

6. The long-acting injectable composition according to any one of claims 1 to 5, wherein the composition comprises a co-solvent, and wherein the co-solvent is ethanol, or isopropanol, or a mixture thereof.

7. The long-acting injectable composition according to claim 1, wherein the composition comprises:

a) 5 to 15% (w/v) of an isoxazoline compound of formula (Ic):



(Ic)

or a pharmaceutically acceptable salt thereof;
wherein
X^1, X^2 and X^3 are each independently halogen, C_1-C_3alkyl or C_1-C_3haloalkyl;

b) a pharmaceutically acceptable polymer which is a liquid PEG;

c) optionally, about 5% to 40% (w/v) of co-solvent, wherein said co-solvent is selected from ethanol and isopropanol;

d) optionally, 0.01% to 2.0 % (w/v) of an antioxidant; and

e) optionally, about 0.01% to 5.0 % (w/v) of a pharmaceutically acceptable additive, excipient or mixtures thereof

wherein the only pharmaceutically acceptable polymer present in said long-acting injectable composition is a liquid PEG and wherein the liquid PEG is present in the overall composition in a proportion representing the complement to 100% of the composition.

8. The long-acting injectable composition according to any one of claims 1 to 7, wherein the parasites are treated or prevented for 3 to 6 months.

9. The long-acting injectable composition according to any one of claims 1 to 7 wherein the parasites are treated or prevented for 5 to 6 months.

10. The long-acting injectable composition according to any one of claims 1 to 7, wherein the parasites are treated or prevented for 6 months.

11. The long-acting injectable composition according to any one of claim 8, 9 or 10 wherein the parasites are fleas or ticks

12. The long-acting composition according to any one of claims 1 to 11, which further comprises an effective amount at least one additional active agent.

13. The long-acting composition according to claim 12, wherein the additional pharmaceutically active agent is a macrocyclic lactone, a neonicotinoid active agent, a 1-N-arylpyrazole active agent, a cyclic depsipeptide, a benzimidazole, an imidazothiazole, a tetrahydropyrimidine active agent, an organophosphate active agent, levamisole, a paraherquamide active agent, a marcfortine active agent, praziquantel, closantel, pyrantel, morantel, clorsulon, a spinosyn active agent, a spinosoid active agent, an amino acetonitrile active agent, an aryloazol-2-yl cyanoethyl active agent or an insect growth regulator.

14. The long-acting composition according to claim 13, wherein the macrocyclic lactone is abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, ML-1,694,554, milbemectin, milbemycin D, moxidectin or nemadectin.

15. A long acting injectable composition according to claim 1 for use in treating or preventing parasites in an animal in need thereof.

16. A long acting injectable composition for use according to claim 15 wherein the animal is a dog, a cat, an ovine or a bovine.

17. A long acting injectable composition for use according to claim 15 wherein the parasites are fleas and/or ticks.